Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases.
BACKGROUND: Anti-angiogenic therapy with bevacizumab (an anti-vascular endothelial growth factor (VEGF) antibody) predominantly targets immature blood vessels. Bevacizumab has shown a survival benefit in non-small cell lung carcinoma (NSCLC) and has recently been demonstrated to be safe in patients...
Huvudupphovsmän: | , , , , , , , |
---|---|
Materialtyp: | Journal article |
Språk: | English |
Publicerad: |
2011
|